General Information of Drug (ID: DMKEV7N)

Drug Name
PK1 Drug Info
Synonyms FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
PubChem CID
59235249
TTD Drug ID
DMKEV7N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Camsirubicin DMEZLFT Soft tissue sarcoma 2B57 Phase 2 [2]
Annamycin DMDHJNV Acute myeloid leukaemia 2A60 Phase 1/2 [3]
NK314 DMY729C T-cell leukaemia 2A90 Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II alpha (TOP2A) TTCGY2K TOP2A_HUMAN Modulator [1]

References

1 Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
2 Clinical pipeline report, company report or official report of Monopar Therapeutics.
3 Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8.
4 NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.